Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lymphoma, B-Cell × Alemtuzumab × Clear all

Phase

Phase NA 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia 10 Lymphoma 9 Precursor Cell Lymphoblastic Leukemia-Lymphoma 8 Myelodysplastic Syndromes 7 Multiple Myeloma 7 Lymphoma, Non-Hodgkin 6 Leukemia, Myeloid, Acute 5 Hodgkin Disease 5 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Neoplasms, Plasma Cell 3 Myeloproliferative Disorders 3 Hematologic Neoplasms 3 Recurrence 2 Paraproteinemias 2 Myelodysplastic-Myeloproliferative Diseases 2 Lymphoproliferative Disorders 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Myeloid, Chronic-Phase 2 Leukemia, Myeloid, Accelerated Phase 2 Congenital Abnormalities 2 Burkitt Lymphoma 2 Anemia, Aplastic 2 Waldenstrom Macroglobulinemia 1 Shwachman-Diamond Syndrome 1 Sezary Syndrome 1 Primary Immunodeficiency Diseases 1 Preleukemia 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cyclophosphamide 25 Rituximab 22 fludarabine 14 Lenalidomide 10 Vincristine 8 Doxorubicin 8 Prednisone 7 Etoposide 7 fludarabine phosphate 6 polatuzumab vedotin 4 Immunotherapy, Adoptive 4 Cytarabine 4 CT-P10 4 Bendamustine Hydrochloride 4 Antigens, CD19 4 tocilizumab 3 Gemcitabine 3 Dexamethasone 3 Carboplatin 3 venetoclax 2 veltuzumab 2 prednylidene 2 ofatumumab 2 obinutuzumab 2 ixazomib 2 ibrutinib 2 etoposide phosphate 2 deltacortene 2 carmustine, poliferprosan 20 drug combination 2 acalabrutinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05607420 2025-08-24

NatHaLi-01

Cellectis S.A.

Phase 1/2 Recruiting

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡